On Tuesday, Raymond (NSE:RYMD) James reaffirmed its Outperform rating and $86.00 price target on Legend Biotech Corp . (NASDAQ:LEGN), following the company’s release of its first-quarter financial ...

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial ...

1 Day LEGN -4.01% DJIA -0.64% S&P 500 0.72% Health Care/Life Sciences -1.52% ...

Legend Biotech Corp (LEGN) reported robust financial results for Q1 2025, driven by significant sales growth of its flagship product, CARVICTI. The company posted total revenues of $195 million, ...

Good day, and thank you for standing by. Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers ...

"We believe our achievements from this past quarter, including capacity expansion and additional global approvals, are setting the stage for Legend Biotech to achieve company-wide profitability by ...

LEGEND BIOTECH ($LEGN) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.07 per share, beating estimates of -$0.23 by $0.16 ...